Abstract
PS-341 (bortezomib) represents a new class of therapeutics that targets the ubiquitin-proteasome pathway. It has broad-spectrum single-agent anticancer activity and can potentiate chemotherapy and radiation in preclinical models. Early phase clinical studies have shown tolerability and activity in multiple myeloma, lymphoma, prostate cancer, and lung cancers. By its mechanism of inhibiting protein degradation, PS-341 targets a wide range of pathways relevant to tumor progression and therapy resistance and can directly modulate expression of cyclins, p27Kip1, p53, nuclear factor-κB, Bcl-2, and Bax. PS-341 is currently in phase I/II clinical development in both non-small cell lung cancer and small cell lung cancer. This article will review the preclinical and clinical experience with PS-341 as it relates to lung cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 40-46 |
| Number of pages | 7 |
| Journal | Seminars in Oncology |
| Volume | 31 |
| Issue number | 1 SUPPL. 1 |
| State | Published - Feb 2004 |
Fingerprint
ASJC Scopus subject areas
- Oncology
Cite this
Proteasome Inhibition with PS-341 (Bortezomib) in Lung Cancer Therapy. / Lara, Primo N; Davies, Angela M.; Mack, Philip; Mortenson, Melinda M.; Bold, Richard J; Gumerlock, Paul H.; Gandara, David R.
In: Seminars in Oncology, Vol. 31, No. 1 SUPPL. 1, 02.2004, p. 40-46.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Proteasome Inhibition with PS-341 (Bortezomib) in Lung Cancer Therapy
AU - Lara, Primo N
AU - Davies, Angela M.
AU - Mack, Philip
AU - Mortenson, Melinda M.
AU - Bold, Richard J
AU - Gumerlock, Paul H.
AU - Gandara, David R
PY - 2004/2
Y1 - 2004/2
N2 - PS-341 (bortezomib) represents a new class of therapeutics that targets the ubiquitin-proteasome pathway. It has broad-spectrum single-agent anticancer activity and can potentiate chemotherapy and radiation in preclinical models. Early phase clinical studies have shown tolerability and activity in multiple myeloma, lymphoma, prostate cancer, and lung cancers. By its mechanism of inhibiting protein degradation, PS-341 targets a wide range of pathways relevant to tumor progression and therapy resistance and can directly modulate expression of cyclins, p27Kip1, p53, nuclear factor-κB, Bcl-2, and Bax. PS-341 is currently in phase I/II clinical development in both non-small cell lung cancer and small cell lung cancer. This article will review the preclinical and clinical experience with PS-341 as it relates to lung cancer.
AB - PS-341 (bortezomib) represents a new class of therapeutics that targets the ubiquitin-proteasome pathway. It has broad-spectrum single-agent anticancer activity and can potentiate chemotherapy and radiation in preclinical models. Early phase clinical studies have shown tolerability and activity in multiple myeloma, lymphoma, prostate cancer, and lung cancers. By its mechanism of inhibiting protein degradation, PS-341 targets a wide range of pathways relevant to tumor progression and therapy resistance and can directly modulate expression of cyclins, p27Kip1, p53, nuclear factor-κB, Bcl-2, and Bax. PS-341 is currently in phase I/II clinical development in both non-small cell lung cancer and small cell lung cancer. This article will review the preclinical and clinical experience with PS-341 as it relates to lung cancer.
UR - http://www.scopus.com/inward/record.url?scp=1242318831&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1242318831&partnerID=8YFLogxK
M3 - Article
VL - 31
SP - 40
EP - 46
JO - Seminars in Oncology
JF - Seminars in Oncology
SN - 0093-7754
IS - 1 SUPPL. 1
ER -